GermanyGermany

Wilex improves result

29.02.2012

Munich – Looking back with satisfaction and bent on a prize for good behaviour, German biopharmaceutical company Wilex AG reported yesterday on the fiscal year 2011 and outlined the shores in sight.
The 2011 total revenue was better than last year (€11.7m, 2010: €1.3m), with the licence agreement from Prometheus Inc. about a therapeutic antibody named Rencarex accounting for the biggest share: In April 2011, Wilex received €19m from the Californian company which in turn, secured the rights to promote the anti-cancer remedy in the US. After an FDA approval last autumn, Rencarex is now on an amended study protocol. If data are positive, Wilex could file for drug approval in Europe and the US in early 2013. As foreseen in the Prometheus deal, the Munich biotech start-up becomes eligible for a €20m payment at the end of April. Whether Wilex grabs the money or instead takes hold of the option to secure the marketing rights in Europe for one–yet unnamed–Prometheus product remains elusive so far.
Data on Wilex' second pipeline drug Mesupron is also nervously anticipated. In a clinical Phase II study, it is being tested on 132 patients with a certain type of breast cancer. The primary endpoint PFS will be accomplished in 2012, data for overall survival will likely be available in 2013. CFO Peter Llewellyn-Davies pointed out that Wilex had diversified its service portfolio: "In 2011 we successfully integrated two acquisitions." One of them, Heidelberg Pharma, is specialised in customer-oriented CR. The other, Oncogene Science successor Wiley Inc., does in vitro diagnostic tests. For 2012 sales are expected to grow from €11.7m up to €16m. However, the operating loss would still remain between €10m and €14m (2011:€13,4m). WestLB research analyst Mark Belsey reports that due to higher revenues and lower operating costs the FY-11 results were slightly better than he expected. For FY-12 his opinion is in line with the company's expectations: His sales forecast lies at €15.6m, EBIT guidance at €-12,7m.

GermanyGermany

07.03.2012

The first of February marked a milestone for Leverkusen-based Bio­frontera AG in more ways than one. It was the first day that Ameluz, the firm’s first approved product, could be sold in German pharmacies. It was also the date...

GermanyGermany

07.03.2012

Darmstadt – German pharmaceutical and chemical company Merck KGaA has set a downbeat tone for 2012. CEO Karl-Ludwig Kley said the recently launched cost-cutting programme and tough economic conditions will weigh on profits this...

GermanyGermany

05.03.2012

Mainz/Leuna – Two biotech concepts were amongst the winners of the recent third round of the Excellence Cluster initiative, which is funded by the German Ministry for Research. In Mainz the champagne corks popped especially loud...

GermanyGermany

05.03.2012

German Merck KGaA has closed a licencing agreement with US-based Threshold Pharmaceuticals Inc. The cooperation centres around the hypoxia­-activated drug TH-302, which is currently being studied in a global Phase III study....

GermanyGermany

17.02.2012

Brussels – European cartilage researchers intensify their cooperation. The 'gristle network' comprises scientists from Belgium, France, Germany and Luxembourg. Its members plan to meet regularly to exchange views and information...

27.01.2012

Thousand Oaks/Munich - Bling bling for blinatumomab. It is a compliment for the European life sciences scene and sad news at the same time. Amgen Inc., the world's largest biotechnology company, agreed to buy Micromet Inc., an...

GermanyGermany

20.01.2012

Martinsried - SHELTER is responsible for the fact that the stocks of 4SC behaved like a rodeo horse on Thursday. The shares rose in several stages up to 63%, only to settle at a mere 43% rise at the end of the day. SHELTER is a...

GermanyGermany

17.01.2012

Ludwigshafen – BASF Plant Science GmbH, the agrochemistry and biotech arm of the world-largest chemistry company, thinks that it has outstayed its welcome in Europe. Over the next two years, most of the green biotechnology...

GermanyGermany

10.01.2012

Munich - It is the accolade for Micromet. The German company, which is listed on the U.S. stock exchange, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the renowned US...

Displaying results 1 to 10 out of 454

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/article/wilex-improves-result.html

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • MEDIGENE3.85 EUR8.15%
  • EVOTEC2.87 EUR7.49%
  • 4SC0.84 EUR5.00%

FLOP

  • CYTOS0.15 CHF-6.25%
  • EPIGENOMICS3.42 EUR-0.87%
  • STRATEC BIOMEDICAL37.50 EUR-0.87%

TOP

  • BIOFRONTERA2.91 EUR29.9%
  • ADDEX3.44 CHF5.8%
  • HBM86.00 CHF3.7%

FLOP

  • PAION2.19 EUR-32.6%
  • CYTOS0.15 CHF-28.6%
  • 4SC0.84 EUR-26.3%

TOP

  • SANTHERA82.00 CHF2269.9%
  • CO.DON2.82 EUR209.9%
  • PAION2.19 EUR154.7%

FLOP

  • CYTOS0.15 CHF-96.2%
  • 4SC0.84 EUR-51.7%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 21.10.2014


Current issue

All issues

Product of the week

Products